BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

620 related articles for article (PubMed ID: 26791934)

  • 1. Improved Release of Celecoxib from High Drug Loading Amorphous Solid Dispersions Formulated with Polyacrylic Acid and Cellulose Derivatives.
    Xie T; Taylor LS
    Mol Pharm; 2016 Mar; 13(3):873-84. PubMed ID: 26791934
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dissolution Performance of High Drug Loading Celecoxib Amorphous Solid Dispersions Formulated with Polymer Combinations.
    Xie T; Taylor LS
    Pharm Res; 2016 Mar; 33(3):739-50. PubMed ID: 26563205
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dissolution of Danazol Amorphous Solid Dispersions: Supersaturation and Phase Behavior as a Function of Drug Loading and Polymer Type.
    Jackson MJ; Kestur US; Hussain MA; Taylor LS
    Mol Pharm; 2016 Jan; 13(1):223-31. PubMed ID: 26618718
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Investigation into Intermolecular Interactions and Phase Behavior of Binary and Ternary Amorphous Solid Dispersions of Ketoconazole.
    Sarpal K; Tower CW; Munson EJ
    Mol Pharm; 2020 Mar; 17(3):787-801. PubMed ID: 31860316
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of polymer type on the dissolution profile of amorphous solid dispersions containing felodipine.
    Konno H; Handa T; Alonzo DE; Taylor LS
    Eur J Pharm Biopharm; 2008 Oct; 70(2):493-9. PubMed ID: 18577451
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Crystallization of amorphous solid dispersions of resveratrol during preparation and storage-Impact of different polymers.
    Wegiel LA; Mauer LJ; Edgar KJ; Taylor LS
    J Pharm Sci; 2013 Jan; 102(1):171-84. PubMed ID: 23132686
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhanced kinetic solubility profiles of indomethacin amorphous solid dispersions in poly(2-hydroxyethyl methacrylate) hydrogels.
    Sun DD; Ju TC; Lee PI
    Eur J Pharm Biopharm; 2012 May; 81(1):149-58. PubMed ID: 22233548
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pairwise polymer blends for oral drug delivery.
    Marks JA; Wegiel LA; Taylor LS; Edgar KJ
    J Pharm Sci; 2014 Sep; 103(9):2871-2883. PubMed ID: 24823790
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of HPMC based polymers performance as carriers for manufacture of solid dispersions using the melt extruder.
    Ghosh I; Snyder J; Vippagunta R; Alvine M; Vakil R; Tong WQ; Vippagunta S
    Int J Pharm; 2011 Oct; 419(1-2):12-9. PubMed ID: 21782911
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Investigation into the Solid-State Properties and Dissolution Profile of Spray-Dried Ternary Amorphous Solid Dispersions: A Rational Step toward the Design and Development of a Multicomponent Amorphous System.
    Baghel S; Cathcart H; O'Reilly NJ
    Mol Pharm; 2018 Sep; 15(9):3796-3812. PubMed ID: 30020788
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An investigation into the role of polymeric carriers on crystal growth within amorphous solid dispersion systems.
    Tian Y; Jones DS; Andrews GP
    Mol Pharm; 2015 Apr; 12(4):1180-92. PubMed ID: 25692314
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tailoring supersaturation from amorphous solid dispersions.
    Li N; Taylor LS
    J Control Release; 2018 Jun; 279():114-125. PubMed ID: 29654798
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of crystal nucleation and growth by water-soluble polymers and its impact on the supersaturation profiles of amorphous drugs.
    Ozaki S; Kushida I; Yamashita T; Hasebe T; Shirai O; Kano K
    J Pharm Sci; 2013 Jul; 102(7):2273-81. PubMed ID: 23658029
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Formulation performance and processability window for manufacturing a dual-polymer amorphous solid dispersion via hot-melt extrusion and strand pelletization.
    Hörmann TR; Jäger N; Funke A; Mürb RK; Khinast JG; Paudel A
    Int J Pharm; 2018 Dec; 553(1-2):408-421. PubMed ID: 30326284
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interaction of Polymers with Enzalutamide Nanodroplets-Impact on Droplet Properties and Induction Times.
    Wilson VR; Mugheirbi NA; Mosquera-Giraldo LI; Deac A; Moseson DE; Smith DT; Novo DC; Borca CH; Slipchenko LV; Edgar KJ; Taylor LS
    Mol Pharm; 2021 Mar; 18(3):836-849. PubMed ID: 33539105
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Understanding the generation and maintenance of supersaturation during the dissolution of amorphous solid dispersions using modulated DSC and
    Baghel S; Cathcart H; O'Reilly NJ
    Int J Pharm; 2018 Jan; 536(1):414-425. PubMed ID: 29183857
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Wetting Kinetics: an Alternative Approach Towards Understanding the Enhanced Dissolution Rate for Amorphous Solid Dispersion of a Poorly Soluble Drug.
    Verma S; Rudraraju VS
    AAPS PharmSciTech; 2015 Oct; 16(5):1079-90. PubMed ID: 25672820
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hydroxypropyl methylcellulose acetate succinate as an exceptional polymer for amorphous solid dispersion formulations: A review from bench to clinic.
    Butreddy A
    Eur J Pharm Biopharm; 2022 Aug; 177():289-307. PubMed ID: 35872180
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of Phase Transformations for Amorphous Solid Dispersions of a Weakly Basic Drug upon Dissolution in Biorelevant Media.
    Elkhabaz A; Sarkar S; Simpson GJ; Taylor LS
    Pharm Res; 2019 Oct; 36(12):174. PubMed ID: 31667638
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of Eudragit EPO and hydroxypropyl methylcellulose on drug release rate, supersaturation, precipitation outcome and redissolution rate of indomethacin amorphous solid dispersions.
    Xie T; Gao W; Taylor LS
    Int J Pharm; 2017 Oct; 531(1):313-323. PubMed ID: 28844901
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.